Early Insights from Commercialization of Gene Therapies in Europe
Strategy Consulting, London SW15 2AW, UK
Kassenärztliche Vereinigung Westfalen Lippe, Dortmund 44141, Germany
Author to whom correspondence should be addressed.
Received: 22 December 2016 / Accepted: 14 February 2017 / Published: 17 February 2017
Note: In lieu of an abstract, this is an excerpt from the first page.
After years of research and development, gene therapies are now becoming a commercial reality with several products approved by European regulatory authorities [...]
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
Share & Cite This Article
MDPI and ACS Style
Touchot, N.; Flume, M. Early Insights from Commercialization of Gene Therapies in Europe. Genes 2017, 8, 78.
Touchot N, Flume M. Early Insights from Commercialization of Gene Therapies in Europe. Genes. 2017; 8(2):78.
Touchot, Nicolas; Flume, Mathias. 2017. "Early Insights from Commercialization of Gene Therapies in Europe." Genes 8, no. 2: 78.
Show more citation formats
Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
[Return to top]
For more information on the journal statistics, click here
Multiple requests from the same IP address are counted as one view.